On October 10, 2023, BioMap, a disruptive life science AI company responsible for building the first and largest protein-centric large language model platform xTrimo, announced a strategic collaboration with Sanofi, a global healthcare and pharmaceutical company, to co-develop cutting-edge AI modules for biotherapeutic drug discovery leveraging BioMap’s AI platform. Wilson Sonsini Goodrich & Rosati advised BioMap on the transaction.

With BioMap’s custom-built foundational models and world-leading AI expertise and Sanofi’s proprietary data, computational innovations in protein engineering, and deep biologics development experience, the companies aim to create advanced AI models and protein LLMs that will enable biologics design and multiparametric optimization. Under the terms of the agreement, BioMap will receive an upfront cash payment and near-term payments for reaching module development milestones from Sanofi, and be eligible to receive payments of over $1 billion based on achievement of pre-clinical development, clinical development, regulatory, and commercial milestones. 

The Wilson Sonsini team that advised BioMap on the transaction included Alex Key, Chi-Fei Wang, Kexi Wang, and Alex DeLaney.

For more information, please see BioMap's press release.